Immix Biopharma Inc

NASDAQ:IMMXUnited States

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a class of Tissue-Specific Therapeutics (TSTx) in oncology and inflammation. Its lead asset, IMX-110, is in Phase Ib/IIa clinical trials for solid tumors in the United States and Australia. IMX-110 is a negatively charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor (which inhibits multiple kinases simultaneously) and induces tumor cell death with an apoptosis inducer (which activates apoptosis, a non-inflammatory programmed cell death pathway), leveraging its TME Normalization Technology, delivered deep into the tumor micro-environment (TME). Its TME Normalization Technology allows its drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its other drug candidates include IMX-111 and IMX-120. IMX-111 and IMX-120 are under development for colorectal cancer and inflammatory bowel disease.

Contact Information

Headquarters

11400 West Olympic Blvd., Suite 200LOS ANGELES, CA, United States 90064

Phone

310-651-8041

Fax

---

Executives

Chairman of the Board, Chief Executive Officer

Ilya Rachman

Scientific Co-Founder

Vladimir Torchilin

Chief Financial Officer, Director

Gabriel Morris

Head - Chemistry, Manufacturing, and Control

Nandan Oza

Acting Chief Medical Officer, Head - Clinical Development

Graham Ross